Patent intelligence · US
US 11234971
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
Patent details — US 11234971
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 1, 2022
- Expiration
- Jan 27, 2042
- Applicant
- Corcept Therapeutics Incorporated
- Claims
- 24
- CPC classes
- A61K, A61K31/337, A61K31/444, A61K31/4545
Quick answer
US 11234971 (Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent) is held by Corcept Therapeutics Incorporated. Status: granted. Granted Feb 1, 2022. Expires Jan 27, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/337, A61K31/444, A61K31/4545, A61K45/06, A61P
More from Corcept Therapeutics Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12370175
Glucocorticoid receptor modulators to treat pancreatic cancer
granted -
US 12370188
Formulations of dazucorilant, a glucocorticoid receptor modulator
granted -
US 12336985
Methods for shrinking pituitary tumors
granted -
US 12290551
Methods for imaging and treatment of somatostatin-receptor positive tumors
granted -
US 12285425
Glucocorticoid receptor modulators to treat cervical cancer
granted -
US 12263169
Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
granted -
US 12226417
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
granted -
US 12226412
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted
Frequently asked questions
What is US patent 11234971?
US 11234971 (Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent) is held by Corcept Therapeutics Incorporated. Status: granted. Granted Feb 1, 2022. Expires Jan 27, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11234971?
Corcept Therapeutics Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 120 pharmaceutical patents for this assignee.
When does US 11234971 expire?
Our index shows an expiration date of Jan 27, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.